Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer.

Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE 3rd.

Cancer Immunol Immunother. 2017 Nov;66(11):1437-1447. doi: 10.1007/s00262-017-2038-3. Epub 2017 Jul 7.

PMID:
28688082
2.

NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016.

VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A.

J Natl Compr Canc Netw. 2016 Nov;14(11):1357-1370.

PMID:
27799507
3.

Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer.

Vargo CA, Berger MJ, Phillips G, Mrozek E.

Support Care Cancer. 2016 Jul;24(7):2913-8. doi: 10.1007/s00520-016-3105-6. Epub 2016 Feb 4.

PMID:
26847349
4.

Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.

Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R.

Oncologist. 2015 Apr;20(4):337-43. doi: 10.1634/theoncologist.2014-0334. Epub 2015 Mar 2.

5.

Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.

Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB.

Support Care Cancer. 2015 Jul;23(7):2019-24. doi: 10.1007/s00520-014-2556-x. Epub 2014 Dec 18.

6.

Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma.

Damodaran S, Mrozek E, Liebner D, Kendra K.

J Natl Compr Canc Netw. 2014 Dec;12(12):1666-70; quiz 1670.

PMID:
25505207
7.

Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial.

Derry HM, Jaremka LM, Bennett JM, Peng J, Andridge R, Shapiro C, Malarkey WB, Emery CF, Layman R, Mrozek E, Glaser R, Kiecolt-Glaser JK.

Psychooncology. 2015 Aug;24(8):958-66. doi: 10.1002/pon.3707. Epub 2014 Oct 21.

8.

A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.

Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy B.

Invest New Drugs. 2014 Dec;32(6):1285-94. doi: 10.1007/s10637-014-0122-5. Epub 2014 Jun 5.

9.

Breast cancer and aging: results of the U13 conference breast cancer panel.

Barginear MF, Muss H, Kimmick G, Owusu C, Mrozek E, Shahrokni A, Ballman K, Hurria A.

Breast Cancer Res Treat. 2014 Jul;146(1):1-6. doi: 10.1007/s10549-014-2994-7. Epub 2014 May 22. Review.

10.

Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.

Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL.

Clin Breast Cancer. 2014 Aug;14(4):228-34. doi: 10.1016/j.clbc.2014.02.005. Epub 2014 Feb 20.

11.

Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.

Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJ.

Breast Cancer Res. 2014 Mar 6;16(2):R23. doi: 10.1186/bcr3622.

12.

Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial.

Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, Emery CF, Layman R, Mrozek EE, Glaser R.

J Clin Oncol. 2014 Apr 1;32(10):1040-9. doi: 10.1200/JCO.2013.51.8860. Epub 2014 Jan 27.

13.

Senior adult oncology, version 2.2014: clinical practice guidelines in oncology .

Hurria A, Wildes T, Blair SL, Browner IS, Cohen HJ, Deshazo M, Dotan E, Edil BH, Extermann M, Ganti AK, Holmes HM, Jagsi R, Karlekar MB, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Weir AB 3rd, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2014 Jan;12(1):82-126.

PMID:
24453295
14.

The challenges of individualized care for older patients with localized breast cancer.

Mrózek E, Povoski SP, Shapiro CL.

Expert Rev Anticancer Ther. 2013 Aug;13(8):963-73. doi: 10.1586/14737140.2013.820568. Review.

PMID:
23984898
15.

Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.

Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RM.

Support Care Cancer. 2013 Oct;21(10):2845-51. doi: 10.1007/s00520-013-1865-9. Epub 2013 Jun 8.

16.

Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.

Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski R.

Support Care Cancer. 2013 Oct;21(10):2679-86. doi: 10.1007/s00520-013-1842-3. Epub 2013 May 19.

17.

Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.

Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL.

Cancer Chemother Pharmacol. 2013 May;71(5):1183-90. doi: 10.1007/s00280-013-2112-2. Epub 2013 Feb 21.

18.

Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue.

He L, Grecula JC, Ling Y, Enzerra MD, Ammirati M, Kendra K, Cavaliere R, Mayr N, McGregor J, Olencki T, Mrozek E, Matharbootham M, Oluigbo C, Phelps MA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Sep 15;905:141-4. doi: 10.1016/j.jchromb.2012.08.013. Epub 2012 Aug 16.

19.

Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.

Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp MV.

Magn Reson Imaging. 2012 Oct;30(8):1059-67. doi: 10.1016/j.mri.2012.04.026. Epub 2012 Aug 11.

20.

Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.

Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL.

Cancer Chemother Pharmacol. 2012 Jul;70(1):49-56. doi: 10.1007/s00280-012-1887-x. Epub 2012 May 22.

21.

Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.

Mrózek E, Layman R, Ramaswamy B, Schaaf L, Li X, Ottman S, Shapiro CL.

Clin Breast Cancer. 2012 Apr;12(2):151-6. doi: 10.1016/j.clbc.2012.01.003.

22.

Senior adult oncology.

Hurria A, Browner IS, Cohen HJ, Denlinger CS, deShazo M, Extermann M, Ganti AK, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir AB 3rd, Wildes T.

J Natl Compr Canc Netw. 2012 Feb;10(2):162-209. No abstract available.

23.

Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL.

Clin Breast Cancer. 2011 Aug;11(4):221-7. doi: 10.1016/j.clbc.2011.03.022. Epub 2011 May 19.

24.

Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancer.

Ramaswamy B, Mrozek E, Kuebler JP, Bekaii-Saab T, Kraut EH.

Invest New Drugs. 2011 Apr;29(2):347-51. doi: 10.1007/s10637-009-9338-1. Epub 2009 Oct 21.

25.

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).

Mrozek E, Kolesar J, Young D, Allen J, Villalona-Calero M, Shapiro CL.

Ann Oncol. 2008 Aug;19(8):1417-22. doi: 10.1093/annonc/mdn154. Epub 2008 Apr 11.

PMID:
18407955
26.

Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.

Puhalla S, Mrozek E, Young D, Ottman S, McVey A, Kendra K, Merriman NJ, Knapp M, Patel T, Thompson ME, Maher JF, Moore TD, Shapiro CL.

J Clin Oncol. 2008 Apr 1;26(10):1691-7. doi: 10.1200/JCO.2007.14.3941. Epub 2008 Mar 3.

PMID:
18316792
27.

Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.

Mrozek E, Ramaswamy B, Young D, Rhoades CA, Kendra K, Allen J, Moore T, Hauger M, Watson H, Merriman N, Nadella P, Villalona-Calero M, Shapiro CL.

Clin Breast Cancer. 2006 Jun;7(2):141-5.

PMID:
16800973
28.

Phase II study of celecoxib in metastatic differentiated thyroid carcinoma.

Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ, Sherman SI, Shah MH.

J Clin Endocrinol Metab. 2006 Jun;91(6):2201-4. Epub 2006 Mar 7.

PMID:
16522694
31.

Survivorship and complications of treatment in breast cancer.

Mrozek E, Shapiro CL.

Clin Adv Hematol Oncol. 2005 Mar;3(3):211-22, 238. Review.

PMID:
16166992
32.

Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients.

Mrózek E, Rhoades CA, Allen J, Hade EM, Shapiro CL.

Ann Oncol. 2005 Jul;16(7):1087-93. Epub 2005 Apr 22.

PMID:
15849219
33.

Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged >or=50 years compared to younger adults with low-risk disease.

Farag SS, Elder PJ, Marcucci G, Penza S, Mrozek E, Molina A, Lin T, Avalos BR, Copelan E.

Bone Marrow Transplant. 2003 Jan;31(2):87-93.

PMID:
12621488
34.

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA.

J Clin Invest. 2000 Jul;106(1):117-24.

35.

Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.

Fehniger TA, Carson WE, Mrózek E, Caligiuri MA.

Blood. 1997 Nov 1;90(9):3647-53.

36.
37.

Der(16)T(1-16) is a nonrandom secondary chromosome aberration in many types of human neoplasia, including myxoid liposarcoma, rhabdomyosarcoma and Philadelphia-chromosome-positive acute lymphoblastic-leukemia.

Mrozek K, Arthur D, Karakousis C, Koduru P, Lebeau M, Pettenati M, Tantravahi R, Mrozek E, Perezmesa C, Rao U, Frankel S, Davey F, Bloomfield C.

Int J Oncol. 1995 Mar;6(3):531-8.

PMID:
21556567
38.

Anti-idiotype antibodies as potential therapeutic agents for human breast cancer.

Bhattacharya-Chatterjee M, Mrozek E, Mukerjee S, Ceriani RL, Kohler H, Foon KA.

Adv Exp Med Biol. 1994;353:139-48. No abstract available.

PMID:
7985532
39.

Antiidiotype (Ab2) vaccine therapy for cutaneous T-cell lymphoma.

Chatterjee M, Mrozek E, Vaickus L, Oseroff A, Stoll H, Russell D, Kohler H, Foon KA.

Ann N Y Acad Sci. 1993 Aug 12;690:376-7. No abstract available.

PMID:
8368761
40.

Trisomy of chromosome 12 in a case of thecoma of the ovary.

Mrózek K, Nedoszytko B, Babińska M, Mrózek E, Hrabowska M, Emerich J, Limon J.

Gynecol Oncol. 1990 Mar;36(3):413-6.

PMID:
2156766
41.

[Cytogenetic studies of families with reproductive failure].

Mrózek K, Mrózek E, Nedoszytko B, Babińska M, Gościniak W, Mielnik J, Limon J.

Wiad Lek. 1989 Oct 1-Nov 1;42(19-21):1014-8. Polish.

PMID:
2638049
42.

[Analysis of the indications for and the results of the cytogenetic tests in 826 patients with suspected chromosome aberrations].

Mrózek K, Mrózek E, Bittel-Dobrzyńska N, Limon J.

Pol Tyg Lek. 1988 Sep 26;43(39):1247-50. Polish. No abstract available.

PMID:
3244582
43.

[Laparoscopy as a criterion of indications for the surgical restoration of fallopian tube patency].

Mielnik J, Adamcio-Deptulska M, Płoszyński A, Mrózek E, Czekała D, Korzon T.

Ginekol Pol. 1988 Apr;59(4):198-201. Polish. No abstract available.

PMID:
2976017
44.

Investigation of selective uptake of polychlorinated biphenyls by Spartina alterniflora Loisel.

Mrozek E Jr, Leidy RB.

Bull Environ Contam Toxicol. 1981 Oct;27(4):481-8. No abstract available.

PMID:
6796156
45.

Reduction of polychlorinated biphenyl toxicity and uptake of carbon-14 activity by plants through the use of activated carbon.

Strek HJ, Weber JB, Shea PJ, Mrozek E Jr, Overcash MR.

J Agric Food Chem. 1981 Mar-Apr;29(2):288-93. No abstract available.

PMID:
6785334
46.

Polychlorinated biphenyls: phytotoxicity, absorption and translocation by plants, and inactivation by activated carbon.

Weber JB, Mrozek E Jr.

Bull Environ Contam Toxicol. 1979 Oct;23(3):412-7. No abstract available.

PMID:
117860

Supplemental Content

Loading ...
Support Center